Canadian clinical trial registry

Go to Health Care Provider version

Centres

Study Description

This study is to assess the effectiveness of two drugs (bortezomib and vorinostat) in addition to standard therapy, for the treatment of infants with a new diagnosis of acute lymphoblastic leukemia. 

The study also looks at the side effects associated with these medications.

Bortezomib is a drug called a "proteasome inhibitor" while vorinostat is a drug called an "HDAC inhibitor".

Inclusion Criteria

• Children younger than 365 days of age with a new diagnosis of acute lymphoblastic leukemia
• They cannot have had prior treatment with other chemotherapies (with exception of a few medications, with limited amount of doses given).
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This study is to assess the effectiveness of molecular targeted therapy (four different possible medications) in addition to standard therapy for patients with a new diagnosis of high-risk neuroblastoma. The study also looks at the side effects associated with these medications.

The study also tests the effects of a drug called DFMO when added to the immunotherapy given as post-consolidation treatment.

Inclusion Criteria

• Age 1 to 22 years
• New diagnosis of high risk neuroblastoma
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

This phase 2 trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT-driven medulloblastoma.

(via: https://childrensoncologygroup.org/acns1422)

Inclusion Criteria

• Patients are between 3 years to 21 years old
• Patient is newly diagnosed with average-risk medulloblastoma  in the WNT subgroup by institutional diagnosis
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

This is a study to find out whether a drug called olaparib (also called a PARP inhibitor) is safe and well tolerated when administered to children and adolescents with solid tumours or brain tumours, when they have come back or are not improving with treatment.

Inclusion Criteria

• Patients are ≥ 6 months to <18 years of age 
• Patients have a solid tumour or brain tumour that has come back (relapsed) or is not improving with treatment (refractory)  
• There is a gene change in the tumour or in the normal cells of the patient that can be called "homologous recombination repair gene mutation"
• The patient can swallow tablets
• Multiple other inclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

The reason for this study is to see if the study medication LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma (neuroblastoma that has come back or is not improving despite treatment). LY3295668 erbumine blocks a protein called Aurora kinase A. Aurora kinase A is thought to contribute to the aggressiveness of neuroblastoma cells. 

The medication will be given either alone or in combination with chemotherapy.

Inclusion Criteria

• Age between 2 and 21 years
• Neuroblastoma that has come back (relapse) or is not improving despite treatments (refractory)
• The child must be able to swallow capsules
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This clinical trial studies whether adding an oral medication called lenvatinib to chemotherapy with ifosfamide/etoposide improves outcomes for patients with osteosarcoma that has come back (relapse). 

Lenvatinib blocks cell proteins and signals directed at blood vessels that help the cancer to survive.

Patients can be treated in two different arms: Arm A: chemotherapy + lenvatinib or  Arm B : chemotherapy. The participants will be divided by chance into those two separate groups through a computerised process. The treating team will NOT decide into which arm a given patient will be assigned. At this time, it is not known which treatment option is best.

Inclusion Criteria

• Age between 2 and 25 years
• Osteosarcoma that has come back (relapse) or is not improving despite treatments (refractory)
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This is a study of two medications taken by mouth, called lenvatinib and everolimus. Lenvatinib blocks cell proteins and signals directed at blood vessels that help the cancer to survive. Everolimus is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. It is called an mTOR inhibitor.

The phase 1 of this study has been completed, and now the phase 2 is on-going to understand the anti-cancer activity of those two medications taken together in patients with Ewing sarcoma, rhabdomyosarcoma or high grade glioma that has come back (relapsed) or is refractory to treatment.

Inclusion Criteria

• Age from 2 years to 21 years
• Diagnosis of Ewing sarcoma, rhabdomyosarcoma or high grade glioma that has come back (relapsed) or is refractory to treatment
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This phase III trial compares the effect of two chemotherapy drug pathways (vinorelbine with vincristine, dactinomycin, and cyclophosphamide (VAC) followed by vinorelbine and cyclophosphamide versus VAC followed by vinorelbine and cyclophosphamide) for the treatment of high risk rhabdomyosarcoma.

Chemotherapy drugs, such as vinorelbine, vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Giving vinorelbine and VAC may kill more tumor cells and adding maintenance therapy after VAC therapy may help get rid of the cancer and/or lower the chance that the cancer comes back.

Inclusion Criteria

• Patients must be =< 50 years of age 
• Study is open to all genders
• Patients with newly diagnosed rhabdomyosarcoma (RMS) of any subtype, meeting "high risk" criteria
• Various bloodwork (bilirubin, creatinine, etc) must be within an acceptable range
• Patients must not be pregnant during the duration of the trial
• Additional inclusion and exclusion criteria may apply and will be reviewed by the study team